Based on the Torrent Pharmaceuticals Limited stock forecast from 0 analysts, the average analyst target price for Torrent Pharmaceuticals Limited is not available over the next 12 months. Torrent Pharmaceuticals Limited’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Torrent Pharmaceuticals Limited is Slightly Bullish , which is based on 10 positive signals and 7 negative signals. At the last closing, Torrent Pharmaceuticals Limited’s stock price was INR 3,207.70. Torrent Pharmaceuticals Limited’s stock price has changed by -1.25% over the past week, -6.79% over the past month and +27.00% over the last year.
No recent analyst target price found for Torrent Pharmaceuticals Limited
No recent average analyst rating found for Torrent Pharmaceuticals Limited
Company Overview Torrent Pharmaceuticals Limited
N/A
N/A
N/A
N/A
INR
India
Adjusted Closing Price for Torrent Pharmaceuticals Limited (TORNTPHARM:NSE)
Loading...
Unadjusted Closing Price for Torrent Pharmaceuticals Limited (TORNTPHARM:NSE)
Loading...
Share Trading Volume for Torrent Pharmaceuticals Limited Shares
Loading...
Compare Performance of Torrent Pharmaceuticals Limited Shares
Frequently Asked Questions About Torrent Pharmaceuticals Limited (TORNTPHARM:NSE) Stock
Stock Target Advisor's fundamental analysis for Torrent Pharmaceuticals Limited's stock is Slightly Bullish .
TORNTPHARM:NSE stock's dividend yield is 0.86%.
Our analysis grades TORNTPHARM:NSE stock's dividend yield at C. This means that TORNTPHARM:NSE stock's dividend yield is above 76% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSE exchange.
Based on this TORNTPHARM:NSE may be a average dividend stock for its sector.
Unfortunately we do not have enough data on TORNTPHARM:NSE's stock to indicate what its average analyst target is.
TORNTPHARM:NSE stock's Price/Earning ratio is 60.80.
Our analysis grades TORNTPHARM:NSE stock's Price / Earning ratio at F. This means that TORNTPHARM:NSE stock's Price/Earning ratio is above 67% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSE exchange.
Based on this TORNTPHARM:NSE may be a overvalued for its sector.
The last closing price of TORNTPHARM:NSE's stock was INR 3,207.70.
The most recent market capitalization for TORNTPHARM:NSE is INR 1,129.64B.
Unfortunately we do not have enough analyst data on TORNTPHARM:NSE's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Torrent Pharmaceuticals Limited's stock.
Sorry, we do not have any data on the number of employees for Torrent Pharmaceuticals Limited.
Sorry we do not have any infomation available on Torrent Pharmaceuticals Limited's address.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior total returns
The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
Superior Dividend Growth
This stock has shown top quartile dividend growth in the previous 5 years compared to its sector
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Torrent Pharmaceuticals Limited (TORNTPHARM:NSE) Stock
Stock Target Advisor's fundamental analysis for Torrent Pharmaceuticals Limited's stock is Slightly Bullish .
TORNTPHARM:NSE stock's dividend yield is 0.86%.
Our analysis grades TORNTPHARM:NSE stock's dividend yield at C. This means that TORNTPHARM:NSE stock's dividend yield is above 76% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSE exchange.
Based on this TORNTPHARM:NSE may be a average dividend stock for its sector.
Unfortunately we do not have enough data on TORNTPHARM:NSE's stock to indicate what its average analyst target is.
TORNTPHARM:NSE stock's Price/Earning ratio is 60.80.
Our analysis grades TORNTPHARM:NSE stock's Price / Earning ratio at F. This means that TORNTPHARM:NSE stock's Price/Earning ratio is above 67% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSE exchange.
Based on this TORNTPHARM:NSE may be a overvalued for its sector.
The last closing price of TORNTPHARM:NSE's stock was INR 3,207.70.
The most recent market capitalization for TORNTPHARM:NSE is INR 1,129.64B.
Unfortunately we do not have enough analyst data on TORNTPHARM:NSE's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Torrent Pharmaceuticals Limited's stock.
Sorry, we do not have any data on the number of employees for Torrent Pharmaceuticals Limited.
Sorry we do not have any infomation available on Torrent Pharmaceuticals Limited's address.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for TORNTPHARM:NSE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
